Fulcrum Therapeutics, Inc. (FULC)
NASDAQ: FULC · Real-Time Price · USD
3.580
-0.140 (-3.76%)
At close: Jul 31, 2026, 4:00 PM EDT
3.590
+0.010 (0.28%)
After-hours: Jul 31, 2026, 7:59 PM EDT
Fulcrum Therapeutics Employees
Fulcrum Therapeutics had 55 employees as of December 31, 2025. The number of employees increased by 10 or 22.22% compared to the previous year.
Employees
55
Change (1Y)
10
Growth (1Y)
22.22%
Revenue / Employee
n/a
Profits / Employee
-$1,545,436
Market Cap
273.14M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 55 | 10 | 22.22% |
| Dec 31, 2024 | 45 | -31 | -40.79% |
| Dec 31, 2023 | 76 | -13 | -14.61% |
| Dec 31, 2022 | 89 | -15 | -14.42% |
| Dec 31, 2021 | 104 | 31 | 42.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| AC Immune | 122 |
| Orchestra BioMed Holdings | 86 |
| Cartesian Therapeutics | 75 |
| InflaRx | 65 |
| Surrozen | 44 |
FULC News
- 2 days ago - Fulcrum Therapeutics Quarterly report: Q2 2026 - Filings
- 3 days ago - Kaplan Fox Notifies Fulcrum Therapeutics, Inc. (FULC) Investors of a Securities Investigation into the Company - Newsfile Corp
- 15 days ago - Kaplan Fox Announces a Securities Investigation into Fulcrum Therapeutics, Inc. (FULC) - Investors Encouraged to Contact the Firm - Newsfile Corp
- 2 months ago - Fulcrum Therapeutics downgraded to Underweight from Overweight at JPMorgan - TheFly
- 2 months ago - Goldman suspends rating on Fulcrum Therapeutics - TheFly
- 2 months ago - Fulcrum Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses - GlobeNewsWire
- 2 months ago - Fulcrum Therapeutics price target lowered to $3 from $8 at BofA - TheFly
- 2 months ago - Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns - Reuters